OBJECTIVE: Early onset familial Alzheimer disease (EOFAD) can be caused by mutations in genes for amyloid precursor protein, presenilin 1 (PSEN1), or presenilin 2 (PSEN2). There is considerable phenotypic variability in EOFAD, including some patients with spastic paraparesis. The objective is to describe clinical and neuropathologic features of a family with a PSEN1 mutation that has been reported previously, without autopsy confirmation, in a single Greek family whose affected members presented with memory loss in their 30s, as well as variable limb spasticity and seizures. METHODS: We prospectively evaluated 2 children (son and daughter) with EOFAD and reviewed medical records on their mother. Archival material from the autopsy of the mother was reviewed and postmortem studies were performed on the brain of the daughter. RESULTS: All 3 individuals in this family had disease onset in their 30s, with cognitive deficits in multiple domains, including memory, language, and attention, as well as less common features such as spastic dysarthria, limb spasticity, and seizures. At autopsy both the mother and her daughter had pathologic findings of Alzheimer disease, and histologic evidence of corticospinal tract degeneration. Genetic studies revealed a mutation in PSEN1 leading to an asparagine to serine substitution at amino acid residue 135 (N135S) in presenilin 1. CONCLUSIONS: This is the first description of neuropathologic findings in EOFAD owing to N135S PSEN1 mutation. The clinical phenotype was remarkable for spastic dysarthria, limb spasticity, and seizures, in addition to more typical features of EOFAD.
OBJECTIVE: Early onset familial Alzheimer disease (EOFAD) can be caused by mutations in genes for amyloid precursor protein, presenilin 1 (PSEN1), or presenilin 2 (PSEN2). There is considerable phenotypic variability in EOFAD, including some patients with spastic paraparesis. The objective is to describe clinical and neuropathologic features of a family with a PSEN1 mutation that has been reported previously, without autopsy confirmation, in a single Greek family whose affected members presented with memory loss in their 30s, as well as variable limb spasticity and seizures. METHODS: We prospectively evaluated 2 children (son and daughter) with EOFAD and reviewed medical records on their mother. Archival material from the autopsy of the mother was reviewed and postmortem studies were performed on the brain of the daughter. RESULTS: All 3 individuals in this family had disease onset in their 30s, with cognitive deficits in multiple domains, including memory, language, and attention, as well as less common features such as spastic dysarthria, limb spasticity, and seizures. At autopsy both the mother and her daughter had pathologic findings of Alzheimer disease, and histologic evidence of corticospinal tract degeneration. Genetic studies revealed a mutation in PSEN1 leading to an asparagine to serine substitution at amino acid residue 135 (N135S) in presenilin 1. CONCLUSIONS: This is the first description of neuropathologic findings in EOFAD owing to N135S PSEN1 mutation. The clinical phenotype was remarkable for spastic dysarthria, limb spasticity, and seizures, in addition to more typical features of EOFAD.
Authors: S Mead; M James-Galton; T Revesz; R B Doshi; G Harwood; E L Pan; J Ghiso; B Frangione; G Plant Journal: Brain Date: 2000-05 Impact factor: 13.501
Authors: A Verkkoniemi; H Kalimo; A Paetau; M Somer; T Iwatsubo; J Hardy; M Haltia Journal: J Neuropathol Exp Neurol Date: 2001-05 Impact factor: 3.685
Authors: Gábor G Kovács; Gianriccardo Trabattoni; Johannes A Hainfellner; James W Ironside; Richard S G Knight; Herbert Budka Journal: J Neurol Date: 2002-11 Impact factor: 4.849
Authors: William S Brooks; John B J Kwok; Jillian J Kril; G Anthony Broe; Peter C Blumbergs; Anthony E Tannenberg; Phillipa J Lamont; Philippa Hedges; Peter R Schofield Journal: Brain Date: 2003-04 Impact factor: 13.501
Authors: Daniela Fortini; Federica Cricchi; Roberto Di Fabio; Maria Damiano; Giovanna Comanducci; Laura Benedetti; Manuela Valoppi; Gaetano S Grieco; Ottavio D'Eugenio; Andrea Celato; Filippo Santorelli; Carlo Casali; Giuseppe A Amabile; Francesco Pierelli Journal: Funct Neurol Date: 2003 Jan-Mar
Authors: P Moretti; A P Lieberman; E A Wilde; B I Giordani; K J Kluin; R A Koeppe; S Minoshima; D E Kuhl; W K Seltzer; N L Foster Journal: Neurology Date: 2004-05-25 Impact factor: 9.910
Authors: S O'Riordan; P McMonagle; J C Janssen; N C Fox; M Farrell; J Collinge; M N Rossor; M Hutchinson Journal: Neurology Date: 2002-10-08 Impact factor: 9.910
Authors: Marissa Natelson Love; David G Clark; J Nicholas Cochran; Kyle A Den Beste; David S Geldmacher; Tammie L Benzinger; Brian A Gordon; John C Morris; Randall J Bateman; Erik D Roberson Journal: Neurobiol Aging Date: 2016-10-03 Impact factor: 4.673
Authors: Miren Altuna; Rosa Larumbe; María Victoria Zelaya; Sira Moreno; Virginia García-Solaesa; Maite Mendioroz; María Antonia Ramos; María Elena Erro Journal: J Neurol Date: 2022-04-19 Impact factor: 6.682
Authors: Steffan K Soosman; Nelly Joseph-Mathurin; Meredith N Braskie; Yvette M Bordelon; David Wharton; Maria Casado; Giovanni Coppola; Holly McCallum; Marc Nuwer; Pedro Coutin-Churchman; Liana G Apostolova; Tammie Benzinger; John M Ringman Journal: Neurobiol Aging Date: 2016-08-08 Impact factor: 4.673
Authors: Dennis P Wall; Rimma Pivovarov; Mark Tong; Jae-Yoon Jung; Vincent A Fusaro; Todd F DeLuca; Peter J Tonellato Journal: BMC Med Genomics Date: 2010-10-29 Impact factor: 3.063
Authors: Thomas Sartoretti; Robert P Ganley; Ruiqing Ni; Patrick Freund; Hanns Ulrich Zeilhofer; Jan Klohs Journal: Front Aging Neurosci Date: 2022-05-02 Impact factor: 5.750
Authors: L Manterola; M Hernando-Rodríguez; A Ruiz; A Apraiz; O Arrizabalaga; L Vellón; E Alberdi; F Cavaliere; H M Lacerda; S Jimenez; L A Parada; C Matute; J L Zugaza Journal: Transl Psychiatry Date: 2013-01-22 Impact factor: 6.222